145 related articles for article (PubMed ID: 31741032)
1. Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia.
Peri AM; Rossio R; Tafuri F; Benzecry V; Grancini A; Reda G; Bandera A; Peyvandi F
Ann Hematol; 2019 Dec; 98(12):2847-2849. PubMed ID: 31741032
[No Abstract] [Full Text] [Related]
2. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Hallek M; Kay NE; Osterborg A; Chanan-Khan AA; Mahler M; Salman M; Wan Y; Sun S; Zhuang SH; Howes A
Future Oncol; 2015; 11(1):51-9. PubMed ID: 24901734
[TBL] [Abstract][Full Text] [Related]
3. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
4. A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment.
Suzuki T; Miyakoshi S; Nanba A; Uchiyama T; Kawamoto K; Aoki S
J Clin Exp Hematop; 2018 Sep; 58(3):136-140. PubMed ID: 30012921
[TBL] [Abstract][Full Text] [Related]
5. Is ibrutinib associated with disseminated cryptococcosis with CNS involvement?
Abid MB; Stromich J; Gundacker ND
Cancer Biol Ther; 2019; 20(2):138-140. PubMed ID: 30148696
[TBL] [Abstract][Full Text] [Related]
6. Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia.
Glavey S; Quinn J; McCloy M; Sargent J; McCartney Y; Catherwood M; Marafioti T; Leader M; Murphy P; Thornton P
Eur J Haematol; 2017 Oct; 99(4):378-380. PubMed ID: 28561533
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
8. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Thompson PA; Burger JA
Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
[TBL] [Abstract][Full Text] [Related]
9. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Tran PN; O'Brien S
Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
[TBL] [Abstract][Full Text] [Related]
10. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
11. Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
Bitar C; Farooqui MZ; Valdez J; Saba NS; Soto S; Bray A; Marti G; Wiestner A; Cowen EW
JAMA Dermatol; 2016 Jun; 152(6):698-701. PubMed ID: 26982511
[TBL] [Abstract][Full Text] [Related]
12. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.
Ghez D; Calleja A; Protin C; Baron M; Ledoux MP; Damaj G; Dupont M; Dreyfus B; Ferrant E; Herbaux C; Laribi K; Le Calloch R; Malphettes M; Paul F; Souchet L; Truchan-Graczyk M; Delavigne K; Dartigeas C; Ysebaert L;
Blood; 2018 Apr; 131(17):1955-1959. PubMed ID: 29437588
[TBL] [Abstract][Full Text] [Related]
13. The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression.
Langerbeins P; Bahlo J; Rhein C; Cramer P; Pflug N; Fischer K; Stilgenbauer S; Kreuzer KA; Wendtner CM; Eichhorst B; Hallek M
Future Oncol; 2015; 11(13):1895-903. PubMed ID: 26161926
[TBL] [Abstract][Full Text] [Related]
14. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH
Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
[TBL] [Abstract][Full Text] [Related]
15. Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.
Sun C; Gao J; Couzens L; Tian X; Farooqui MZ; Eichelberger MC; Wiestner A
JAMA Oncol; 2016 Dec; 2(12):1656-1657. PubMed ID: 27533065
[No Abstract] [Full Text] [Related]
16. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
17. Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook.
Faisal MS; Shaikh H; Khattab A; Albrethsen M; Fazal S
J Oncol Pharm Pract; 2019 Sep; 25(6):1486-1490. PubMed ID: 30045683
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.
Mannis G; Wu D; Dea T; Mauro T; Hsu G
Am J Hematol; 2015 Feb; 90(2):179. PubMed ID: 24890909
[No Abstract] [Full Text] [Related]
19. Ibrutinib has some activity in Richter's syndrome.
Giri S; Hahn A; Yaghmour G; Martin MG
Blood Cancer J; 2015 Jan; 5(1):e277. PubMed ID: 25635530
[No Abstract] [Full Text] [Related]
20. Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia.
Stankowicz M; Banaszynski M; Crawford R
J Oncol Pharm Pract; 2019 Apr; 25(3):710-714. PubMed ID: 29343153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]